Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards Publisher Pubmed

Nabavi SF¹ ; Sahebnasagh A² ; Shahbazi A³ ; Nabavi SM¹ ; Azimi S⁴ ; Kashani MK⁵ ; Habtemariam S⁶ ; Rahmani M⁷ ; Badiee M⁷ ; Hashemi J⁸ ; Saghafi F⁹ ; Amini K¹⁰ ; Azimi M¹¹ ; Rezabakhsh A¹²

Source: Current Medicinal Chemistry Published:2023

Abstract

Given the importance of COVID-19-induced ARDS, recently, researchers have strived to determine underlying mechanisms involved in the inflammatory responses. In this regard, inflammasomes possess a distinct priority for cytokine storm occurrence and, subsequently, ARDS progression in ill patients with SARS-CoV-2 infection. In this minireview, the characteristics of known inflammasome inhibitors and designed research in this field were concretely deciphered. © 2023 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Nlrp3 Inflammasome Pathway in Atherosclerosis: Focusing on the Therapeutic Potential of Non-Coding Rnas, Pathology Research and Practice (2023)

2. Pathological Effects of Sars-Cov-2 on Hematological and Immunological Cells: Alterations in Count, Morphology, and Function, Pathology Research and Practice (2022)

3. Nlrp3 Inflammasomes Pathway: A Key Target for Metformin, Inflammopharmacology (2025)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (4)

Mohammad Sharifzadeh (1)

Other Related Docs

4. Th17 and Treg Cells Function in Sars-Cov2 Patients Compared With Healthy Controls, Journal of Cellular Physiology (2021)

5. Immune-Based Therapy for Covid-19, Advances in Experimental Medicine and Biology (2021)

6. The Impact of Covid-19 on Diagnostic Biomarkers in Neuropsychiatric and Neuroimmunological Diseases: A Review, Reviews in the Neurosciences (2022)

7. Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics, International Immunopharmacology (2020)

8. Formation and Activity of Nlrp3 Inflammasome and Histopathological Changes in the Lung of Corpses With Covid-19, Journal of Molecular Histology (2022)

9. Sars-Cov-2 Nucleocapsid: Biological Functions and Implication for Disease Diagnosis and Vaccine Design, Reviews in Medical Virology (2023)

10. Classification of the Present Pharmaceutical Agents Based on the Possible Effective Mechanism on the Covid-19 Infection, DARU# Journal of Pharmaceutical Sciences (2020)

11. Cytokine Profiles Dynamics in Covid-19 Patients: A Longitudinal Analysis of Disease Severity and Outcomes, Scientific Reports (2025)

12. Association Between Serum Inflammatory Parameters and the Disease Severity in Covid-19 Patients, Journal of Clinical Laboratory Analysis (2022)

13. Repurposing Metformin for Covid-19 Complications in Patients With Type 2 Diabetes and Insulin Resistance, Immunopharmacology and Immunotoxicology (2021)

14. The Situation of Small Molecules Targeting Key Proteins in Combatting Sars-Cov-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications, Mini-Reviews in Medicinal Chemistry (2022)

15. Immunosenescence and Inflamm-Ageing in Covid-19, Ageing Research Reviews (2023)

16. Can Anti-Parasitic Drugs Help Control Covid-19?, Future Virology (2022)

17. Coronavirus Disease 2019 (Covid-19) in Pediatric Patients With Autoimmune Disorders, European Journal of Pediatrics (2023)

18. Thrombotic Storm in Coronavirus Disease 2019: From Underlying Mechanisms to Its Management, Journal of Medical Microbiology (2022)

19. Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities, Cytokine (2025)

20. Towards Treatment Planning of Covid-19: Rationale and Hypothesis for the Use of Multiple Immunosuppressive Agents: Anti-Antibodies, Immunoglobulins, and Corticosteroids, International Immunopharmacology (2020)

Style	Citing Format
MLA	Nabavi SF, et al.. "Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards." Current Medicinal Chemistry, vol. 30, no. 12, 2023, pp. 1406-1419.
APA	Nabavi SF, Sahebnasagh A, Shahbazi A, Nabavi SM, Azimi S, Kashani MK, Habtemariam S, Rahmani M, Badiee M, Hashemi J, Saghafi F, Amini K, Azimi M, Rezabakhsh A (2023). Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards. Current Medicinal Chemistry, 30(12), 1406-1419.
Chicago	Nabavi SF, Sahebnasagh A, Shahbazi A, Nabavi SM, Azimi S, Kashani MK, Habtemariam S, et al.. "Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards." Current Medicinal Chemistry 30, no. 12 (2023): 1406-1419.
Harvard	Nabavi SF et al. (2023) 'Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards', Current Medicinal Chemistry, 30(12), pp. 1406-1419.
Vancouver	Nabavi SF, Sahebnasagh A, Shahbazi A, Nabavi SM, Azimi S, Kashani MK, et al.. Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards. Current Medicinal Chemistry. 2023;30(12):1406-1419.
BibTex	@article{ author = {Nabavi SF and Sahebnasagh A and Shahbazi A and Nabavi SM and Azimi S and Kashani MK and Habtemariam S and Rahmani M and Badiee M and Hashemi J and Saghafi F and Amini K and Azimi M and Rezabakhsh A}, title = {Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards}, journal = {Current Medicinal Chemistry}, volume = {30}, number = {12}, pages = {1406-1419}, year = {2023} }
RIS	TY - JOUR AU - Nabavi SF AU - Sahebnasagh A AU - Shahbazi A AU - Nabavi SM AU - Azimi S AU - Kashani MK AU - Habtemariam S AU - Rahmani M AU - Badiee M AU - Hashemi J AU - Saghafi F AU - Amini K AU - Azimi M AU - Rezabakhsh A TI - Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards JO - Current Medicinal Chemistry VL - 30 IS - 12 SP - 1406 EP - 1419 PY - 2023 ER -

Science Communicator Platform

Authors

Abstract